← Leaderboards
Guangfu Li
University Of Missouri-Columbia
$3,084,117
Attributed
$7,482,649
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2017–25$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,482,649 · 4
By mechanism
R01$7,482,649 · 4
Top collaborators
- Kevin Finnbar Staveleyo'Carroll16 shared
- Mark Kester5 shared
- Randy Scott Rector3 shared
Most similar at University Of Missouri-Columbia
Same institution · by research overlap
- Randy Scott Rector$3,318,467
Others in their field
Other Emerging Leaders on “Molecular”
- Leonard Freedman · Leidos Biomedical Research, Inc.$468,573,385
- Lynn Briscoe · Leidos Biomedical Research, Inc.$137,360,557
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$109,548,439
- Leonard Freedmand · Leidos Biomedical Research, Inc.$85,594,314
- Peter W Pisters · University Of Tx Md Anderson Can Ctr$76,895,673
- Scott Hensley · University Of Pennsylvania$41,662,743
Research focus
MolecularMacrophageLiverMediatingImmuneImmune ResponseImmune ToleranceTumorTreatment EfficacyTumor AntigensTumor ImmunityPrimary Carcinoma Of The Liver CellsTumor ProgressionCancer InitiationTherapeutic EffectImmunotherapyMalignant NeoplasmsTumor GrowthCd8-Positive T-LymphocytesGrowthImmune ActivationTreatment ResponseGut MicrobiotaMicrobe
Grant awards (16)
Targeting KLF2 in macrophages to improve immune checkpoint therapy for hepatocellular cancer$627,562
R01 · FY2025 · CA · contact PI
Mechanistic studies of gut microbiota-mediated immune activation against hepatocellular cancer$488,308
R01 · FY2025 · CA
Mechanistic studies of gut microbiota-mediated immune activation against hepatocellular cancer$474,805
R01 · FY2024 · CA
Mechanisms of gut microbiota/metabolite interface-mediated hepatic inflammation$397,590
R01 · FY2024 · DK · contact PI
Mechanistic studies of gut microbiota-mediated immune activation against hepatocellular cancer$457,731
R01 · FY2023 · CA
Mechanisms of gut microbiota/metabolite interface-mediated hepatic inflammation$394,466
R01 · FY2023 · DK · contact PI
Targeting KLF2 in macrophages to improve immune checkpoint therapy for hepatocellular cancer$330,192
R01 · FY2023 · CA · contact PI
Targeting KLF2 in macrophages to improve immune checkpoint therapy for hepatocellular cancer$237,330
R01 · FY2023 · CA · contact PI
Mechanistic studies of gut microbiota-mediated immune activation against hepatocellular cancer$459,004
R01 · FY2022 · CA
Mechanisms of gut microbiota/metabolite interface-mediated hepatic inflammation$400,000
R01 · FY2022 · DK · contact PI
Combination of ceramide and immunotherapy in treatment of hepatocellular cancer$553,074
R01 · FY2021 · CA
Mechanistic studies of gut microbiota-mediated immune activation against hepatocellular cancer$464,474
R01 · FY2021 · CA
Combination of ceramide and immunotherapy in treatment of hepatocellular cancer$569,928
R01 · FY2020 · CA
Combination of ceramide and immunotherapy in treatment of hepatocellular cancer$551,141
R01 · FY2019 · CA
Combination of ceramide and immunotherapy in treatment of hepatocellular cancer$545,802
R01 · FY2018 · CA
Combination of ceramide and immunotherapy in treatment of hepatocellular cancer$531,242
R01 · FY2017 · CA